Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antifungal
Biotech
Basilea scores $268M BARDA funding for antifungals, antibiotics
In the near term, the company will get $29 million to develop its antifungals fosmanogepix and BAL2062.
James Waldron
Sep 19, 2024 7:45am
F2G raises $100M for 2nd attempt to get new antifungal to market
Sep 12, 2024 8:58am
Pfizer cuts 3 assets as R&D spend drops 24% in Q4
Jan 30, 2024 11:37am
Basilea continues pipeline refill with Pfizer antifungal
Nov 13, 2023 8:15am
Basilea anti-infective strategy restarts with $2M antifungal buy
Oct 19, 2023 7:25am
FDA stalls F2G's plans to get new class of antifungal to market
Jun 20, 2023 9:30am
